BiondVax announces financial plans to support its ongoing NanoAb pipeline developmentPRNewsWire • 09/30/22
BiondVax's Strategic Research Collaboration with Max Planck and UMG: Significant progress towards development of innovative nanosized antibodies (NanoAbs) for therapeutic indications in addition to COVID-19PRNewsWire • 09/20/22
BiondVax announces Second Quarter 2022 Financial Results and Provides Business UpdatePRNewsWire • 08/25/22
BiondVax and European Investment Bank sign definitive amendment extending maturity of loan until December 2027 with additional terms in support of BiondVax's new strategyPRNewsWire • 08/10/22
BiondVax receives supportive Scientific Advice from the Paul Ehrlich Institute (PEI) for COVID-19 NanoAb development plans including first-in-human Phase 1/2a safety and efficacy clinical trialPRNewsWire • 06/07/22
BiondVax Announces First Quarter 2022 Financial Results and Provides Business UpdatePRNewsWire • 06/01/22
BiondVax Provides Update at Biomed Israel Conference and Announces Significant Progress in its Nanosized Antibodies ProgramPRNewsWire • 05/12/22
BiondVax Pharmaceuticals Ltd. (BVXV) CEO Amir Reichman on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 04/04/22
BiondVax Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business UpdatePRNewsWire • 03/28/22
BiondVax signs definitive collaboration agreement for the development of a pipeline of innovative nanosized antibody (NanoAb) therapiesPRNewsWire • 03/24/22
European Investment Bank Agrees in Principle to Extend the Maturity of its Loan until December 2027 with Additional Terms that Provide Continued Long-Term Support for BiondVax's New StrategyPRNewsWire • 03/14/22
Aegis Capital Corp. Acted as Sole Bookrunner on a $9.8 Million Underwritten Public Offering of ADSs for BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)Accesswire • 01/03/22
BiondVax Announces Successful Closing of $9.8 million Follow-on Underwritten Offering of ADSs Including Exercise of the Over-AllotmentPRNewsWire • 12/29/21